RNA Interference against ATP as a Gene Therapy Approach for Prostate Cancer
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Shuangya Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China. Hauptthemen laut MEDLINE: Adenosine Triphosphate, Prostatic Neoplasms. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Wenzhou Municipal Science and Technology Bureau, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Chemotherapeutic agents targeting energy metabolism have not achieved satisfactory results in different types of tumors. Herein, we developed an RNA interference (RNAi) method against adenosine triphosphate (ATP) by constructing an interfering plasmid-expressing ATP-binding RNA aptamer, which notably inhibited the growth of prostate cancer cells through diminishing the availability of cytoplasmic ATP and impairing the homeostasis of energy metabolism, and both glycolysis and oxidative phosphorylation were suppressed after RNAi treatment. Further identifying the mechanism underlying the effects of ATP aptamer, we surprisingly found that it markedly reduced the activity of membrane ionic channels and membrane potential which led to the dysfunction of mitochondria, such as the decrease of mitochondrial number, reduction in the respiration rate, and decline of mitochondrial membrane potential and ATP production. Meanwhile, the shortage of ATP impeded the formation of lamellipodia that are essential for the movement of cells, consequently resulting in a significant reduction of cell migration. Both the downregulation of the phosphorylation of AMP-activated protein kinase (AMPK) and endoplasmic reticulum kinase (ERK) and diminishing of lamellipodium formation led to cell apoptosis as well as the inhibition of angiogenesis and invasion. In conclusion, as the first RNAi modality targeting the blocking of ATP consumption, the present method can disturb the respiratory chain and ATP pool, which provides a novel regime for tumor therapies..
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
- Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
- Pharmaceutical Department, Jinhua Central Hospital, Jinhua, Zhejiang 321000, China.
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong 510006, China.
ORCID-Profile: Xiaokun Li, Zhiyuan Fang, Cong Wang
Förderung
- Wenzhou Municipal Science and Technology Bureau
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Chen, S., Ma, J., Xiao, Y., Zhou, D., He, P., Chen, Y., Zheng, X., Lin, H., Qiu, F., Yuan, Y., Zhong, J., Li, X., Pan, X., Fang, Z., & Wang, C. (2023). RNA Interference against ATP as a Gene Therapy Approach for Prostate Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00587
Vancouver
Chen S, Ma J, Xiao Y, Zhou D, He P, Chen Y, et al. RNA Interference against ATP as a Gene Therapy Approach for Prostate Cancer. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00587
BibTeX
@article{Chen2023,
author = {Chen, Shuangya and Ma, Jisheng and Xiao, Yunbei and Zhou, Dongyan and He, Ping and Chen, Yajing and Zheng, Xiaolu and Lin, Hui and Qiu, Feng and Yuan, Yuying and Zhong, Jiaben and Li, Xiaokun and Pan, Xuebo and Fang, Zhiyuan and Wang, Cong},
title = {RNA Interference against ATP as a Gene Therapy Approach for Prostate Cancer},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00587}
}
EUVIMED